Pop T, Treese N
Drugs. 1985;29 Suppl 4:1-6. doi: 10.2165/00003495-198500294-00002.
Sixteen patients were investigated by means of programmed atrial stimulation at 2 different driving rates: 100/min and 120/min. All patients had an increased atrial vulnerability at both driving rates. After the administration of intravenous flecainide (1 mg/kg bodyweight as a bolus, followed by the same amount infused over a period of 20 minutes), the increased vulnerability was abolished in 11 and 9 patients, respectively. In the remaining patients the rate of induced atrial tachyarrhythmia decreased. These findings correlate with a significant prolongation of the effective refractory period of the right atrium and a corresponding significant shortening of its relative refractory period. It is concluded that flecainide may be effective in the treatment of atrial arrhythmias in humans.
16名患者通过程控心房刺激以两种不同的驱动频率进行研究:100次/分钟和120次/分钟。所有患者在这两种驱动频率下心房易损性均增加。静脉注射氟卡尼(1mg/kg体重推注,随后在20分钟内输注相同剂量)后,分别有11例和9例患者的易损性增加被消除。其余患者诱发房性快速心律失常的发生率降低。这些发现与右心房有效不应期的显著延长及其相对不应期的相应显著缩短相关。结论是氟卡尼可能对治疗人类房性心律失常有效。